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A B S T R A C T
Metabolic syndrome (MS) is a combination of risk factors that are associated with several chronic diseases. Its compo-
nents (obesity, dyslipidemia, carbohydrate intolerance, hypertension, microalbumineria) are diverse, whose thresholds
vary in different definitions of MS. For example, a World Health Organization (WHO) panel defined the obesity compo-
nent of MS based on waist-hip ratio, or body mass index (BMI), while the National Cholesterol Education Program
(NCEP) defined the obesity component of MS by waist circumference. Since BMI is the common measure of obesity in
most epidemiological studies, this research addressed how accurately the obesity component of MS is captured by BMI
alone. Data presented showed that in a population with high prevalence of obesity , the specificity of detecting the obesity
component of MS by BMI alone is almost 100%, but the sensitivity is low (e.g., <50%). Individuals with high BMI gener-
ally have large waist-hip ratio and wide waist circumference, but the converse is not necessarily true. Consequently, cen-
tralized obesity (a risk factor for several chronic diseases) is not always captured by a high BMI alone.
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Introduction
Recent reviews indicate that frequent co-morbidity of
obesity, diabetes, hypertension, and hyperlipidemia in in-
dividuals was first noted in late 1960s, which was subse-
quently called »metabolic syndrome« (MS) in late 1970s1–4.
Though at first MS was thought to be associated with
atherosclerosis, its additional connection with insulin re-
sistance lead to the terminology of »insulin resistance
syndrome«, also called »syndrome X«5,6. Subsequent stu-
dies indicate that, irrespective of the term used (Syn-
drome X, Insulin resistance syndrome, or metabolic syn-
drome), the phenomenon of concern is a clustering of
risk factors, whose major components are: obesity, dys-
lipidemia, carbohydrate intolerance, hypertension, and
microalbumineria that are, in aggregate, closely associ-
ated with atherosclerosis, coronary heart disease, hyper-
glycemia, and insulin resistance.
As these diseases are generally classified as metabolic
disorders, the term metabolic syndrome (MS) has be-
come the most commonly used description of these
clustered co-morbid risk factors. However, not until the
attempts of the experts’ panel of the World Health Orga-
nization (WHO) in 1998, and that of the National Choles-
terol Education Program Adult Treatment Panel III
(NCEP-ATP III) in 2001, criteria for defining MS in
adults were established formally7,8. Though the WHO
definition was subsequently modified in 1999 in conjunc-
tion with the European Group for the Study of Insulin
Resistance (EGIR)9, there are important differences of
case definition and prognostic ability in using the criteria
of WHO versus that of NCEP-ATP III10,11.
As a consequence, studies on the prevalence of MS,
judged by both WHO and NCEP-ATP III definitions, of-
ten produce conflicting results. For example, an almost
2-fold increased prevalence of MS according to the
NCEP-ATP III definition, as compared to that of the
WHO definition has been reported in Mexico (age-ad-
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justed rate 26.6% versus 13.6%)12, while in the San Anto-
nio Heart study cohort, the crude rates of MS by both
definitions were almost the same (25%)13. Almost equal
prevalence of MS by these two definitions (crude rate of
81% by the NCEP-ATP III, versus 78% by the WHO cri-
teria) were also seen in a series of type 2 diabetes pa-
tients in Italy14, but among the Arab-Americans a reverse
trend; namely, a lower rate of MS (23% age adjusted)
with the NCEP-ATP III criteria in comparison to the
age-adjusted rate of 28% by the WHO definition, has
been noted15. Such a reverse trend was also noted in a
study of adolescents of Greater Cincinnati region, where
the crude prevalence of WHO-defined MS was exactly
double (8.4%) of that defined by the NCEP-ATP III crite-
ria (4.2%)16. Though this study was conducted in a popu-
lation of mixed ethnic origin (consisting of Black, White,
and Hispanic school children, 7th through 12th grades),
their NCEP-ATP III criteria based prevalence rate of MS
agrees fairly with that of the adolescent study from the
third NHANES survey17. In addition, regardless of preva-
lence rates, the congruence of classifying individuals as
having MS or not by these two definitions has been at
best modest (e.g., the -statistic has been reported in the
range of 0.41–0.50)12,16.
These discrepancies prompted some researchers to
conclude that MS, as defined by these two guidelines,
may not be caused by a common etiologic mechanism16.
However, ethnic variations of MS in general, and more so
of its individual components7, argue that such criticisms
may not be totally valid, since the sensitivity and speci-
ficity of detection of MS may be dependent on the mea-
sures of each component of MS and their cut-off values.
As central adiposity has been shown to determine the
prevalence differences of MS18, and weight loss has a sig-
nificant impact on the syndrome itself19, the purpose of
this research is to examine how a specific measure of obe-
sity, an important component of MS, impacts the sensi-
tivity and specificity of the detection of the obesity com-
ponent of the MS. In particular, using data on a random
sample of 992 Mexican American men and women, aged
15 through 75 years of age, as described in earlier re-
search20–22, we show that the most popular measure of
obesity; namely, the body mass index (BMI = Weight /
Height2, with weight measured in kilograms, and height
in meters) determines the obesity component of MS by
both WHO and NCEP-ATP III definitions of MS with al-
most perfect (100%) specificity, but sensitivity is at best
modest (28.3 to 45.9% for the WHO definition, and 43.2
to 77.1% for the NCEP-ATP III definition, depending
upon age and gender). Thus, we argue that for defining
MS, BMI alone is not an adequate indicator of obesity; it
must be supplemented by measures of centralized obe-
sity, such as the waist circumference, or the waist-hip ra-
tio. This is so, because individuals with low or moderate
BMI generally have low waist-hip ratio (WHR) and waist
circumference (WC), but in contrast obesity may be due
to higher WHR and/or wide WC (i.e., centralized obesity)
without BMI being high (i.e., without being obese in gen-
eral).
Materials and Methods
Definition of MS and its obesity component
The definition of MS, according to the WHO criteria
has two components. First, for an individual to be classi-
fied as having MS, the person must have hyperinsuline-
mia (defiend as the upper quartile of the nondiabetic
population), a post 2-hour glucose load 140 mg.dL, a
fasting plasma glucose 110 mg/dL, or taking medication
for diabetes. In addition, the person must have at least
two of the following abnormalities; general or abdominal
obesity (i.e., either BMI 30 kg/m2, or a waist-hip ratio
(WHR) >0.90 in men, or >0.85 for females), dyslipide-
mia (i.e., triglycerides 150 mg/dL, and /or HDL choles-
terol <35 mg/dL in men, or <39 mg/dL in women), high
blood pressure (i.e., 140/90 mm Hg), or microalbumi-
nuria (i.e, urinary albumin excretion rate 20 g/min, or
albumin/creatine ratio 30 mg/g). Thus, the WHO-defi-
nition of MS is somewhat complex, as it consists of insu-
lin resistance as the essential element, and the obesity
component is either general (determined by high BMI),
or centralized adiposity (e.g., with large WHR)7.
In contrast, the NCEP-ATP III criteria of MS are sim-
pler. According to this, individuals who has 3 or more of
the following abnormalities would be called having MS:
hyperglycemia (i.e., fasting glucose 110 mg/dL), abdom-
inal obesity (i.e., waist circumference, WC >102 cm in
men, or >88 cm for women), triglycerides 150 mg/dL,
low HDL cholesterol (i.e., HDL <40 mg/dL in men, or <
50 mg/dL in women), high blood pressure (HBP,  130/ 
85 mm Hg)8. Thus, the two definitions of MS differ with
respect to the components (e.g., albumin abnormality is
included in the WHO definition, but not in NCEP ATP
III; hyperglycemia and/or diabetes is essential for the
WHO definition, but not a necessary condition for the
NCEP ATP III; and obesity pattern can be either general
or centralized according to the WHO definition, but only
needs to be centralized according to the NCEP ATP III
criteria). Further differences are in the cut-off values for
several components (e.g., the designations of HBP and
low HDL are different). In addition, even the measure
used to define centralized adiposity is different between
them (WHR versus WC). Numerous studies showed eth-
nic as well as demographic differences of variation with
respect to these different components of MS, and hence,
it is not surprising that the prevalence of MS by these
two definitions show a somewhat discrepant trend, de-
pending upon age, gender, and ethnicity of the subjects
studied.
For the analysis of the present study, we consider the
three measures of obesity (e.g., BMI 30 kg/m2; WHR >
0.90 in men, or >0.85 for females; and WC >102 cm in
men, or >88 cm for women). We address the question of
sensitivity and specificity of determining the obesity
component of the WHO- and NCEP ATP III-definitions
of MS, by using the BMI criterion alone, since weight loss
(i.e. reduction of BMI) appears to be the most popular
suggested intervention modality for controlling MS in
population-based studies19.
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Study population and data used
To examine the utility of BMI alone for detecting
WHO- or NCEP ATP III-based criterion of the obesity
component of MS, we use the data gathered in the gall-
bladder genetic epidemiology study among the Mexican
Americans of Starr County, Texas20–22. Statistical fea-
tures of different measures of body fat distribution in
this sample have been reported earlier along with a study
of the validity of the use of body silhouettes for distin-
guishing abdominal and lower body obesity and their re-
lationship with type 2 diabetes and gallbladder disea-
se22,23. In this survey, over 1000 Mexican Americans from
Starr County were randomly sampled to measure their
body fat distribution and determine the prevalence of
obesity, type-2 diabetes, and gallbladder disease. Of the-
se, for 992 individuals, aged 15 to 75 years (296 males,
and 696 females), measurements were available for waist
and hip circumference, height, and weight, so that BMI,
WHR, and WC could all be computed for the purpose of
the present analyses. The survey design, description of
the study population, and details of physical examination
and measurement procedures were described earlier20–23.
For the purpose of the present analyses, summary results
are presented by classifying the sampled individuals by
gender and two age groups (15–44 yrs, and 45–75 yrs.),
although for some analyses (e.g., correlations between
the different measures of body fat distribution) age-ad-
justment was done by considering the exact age of each
individual. Table 1 shows the sample sizes of the data an-
alyzed in the present study.
Statistical methods
Descriptive statistics of the three measures of body
fat distribution (BMI = Weight/Height2, with weight
measured in kg, and height in meters; WHR = Ratio of
waist and hip circumference; and WC = Waist Circum-
ference in cms) were computed to depict the general
characteristics of body fat pattering in the sample. Age-
adjusted (i.e., linear effect of age on each body fatness
variable removed by regression analyses) values of BMI,
WHR, and WC were used to compute their product-mo-
ment correlations. Using the cut-of values for the obesity
component of MS according to the WHO definition (i.e.,
either BMI 30 kg/m2, or a WHR >0.90 in men, or >0.85
for females), and by the NCEP ATP III definition (i.e.,
WC >102 cm in men, or >88 cm for women), the obesity
component of metabolic syndrome (MS-obesity) was de-
fined for each definition. Standard epidemiological defi-
nitions of sensitivity and specificity were used for detect-
ing these two types of MS-obesity criteria by classifying
individuals as obese by BMI testing alone (i.e., BMI 30
kg/m2)24. All analyses were done by using the respective
modules of the SPSS-v.10 software.
Results
Descriptive statistics of obesity variables
Table 2 shows the descriptive statistics (mean and
s.d.) of the three measures of body fatness, and age, for
males and females separately. Roughly, the study sample
consists of men and women, both approximately 40 years
old, on average. On an average, both males and females
in this sample are in the mid over-weight category (i.e.,
BMI between 25 to 30 kg/m2). Average WHR exceeds the
WHO criteria of MS-obesity for both males and females.
In other words, according to the WHO criteria of abdomi-
nal obesity, an average male or female of this sample
would be called obese. In contrast, the mean WC exceeds
the NCEP ATP III criterion of abdominal obesity for
women, but not for the men. In other words, women of
this sample are on an average MS-obese by the NCEP
ATP III criterion, but not the men in general.
Inter-relationships between the obesity measures
Table 3 presents the age-adjusted product-moment
correlations between the three obesity variables (BMI,
WHR, and WC) for males and females, separately. It is
clear that WHR is comparatively less correlated with
BMI and WC, while in both men and women BMI and
WC are more strongly correlated. The more modest cor-
relation between BMI and WHR, in a sense justifies the
inclusion of BMI- and/or WHR-based measures of the
obesity component in the WHO definition of MS, since
with this definition both general and centralized form of
body fat distribution can be covered. Nonetheless, the
correlation structure shown in the data of Table 3 is con-
sistent with the common notion that BMI captures a gen-
eral form of obesity, while WHR and WC are perhaps a
better description of centralized obesity.
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TABLE 1
SAMPLE SIZES BY AGE AND SEX
Age Males Females Total
15 – 44 yrs 193 426 619
45 – 75 yrs 103 270 373
Total 296 696 992
TABLE 2




n Mean (s.d.) n Mean (s.d.)
Age 299 39.75 (15.79) 699 40.41 (15.22)
WC 291 96.87 (13.67) 678 95.85 (16.64)
BMI 298 27.28 (5.84) 699 27.59 (5.92)
WHR 291 0.95 (0.07) 678 0.91 (0.09)
Age in years, WC = Waist circumference (in cm), BMI – Body
Mass Index = Weight/Height
Sensitivity and specificity of BMI-based detection
of the obesity component of MS
Using the definition of the obesity component of MS
in the WHO and NCEP ATP III definitions, we deter-
mined the sensitivity and specificity indices when obesity
is tested by BMI alone (i.e., BMI 30 kg/m2). The sum-
mary results are shown in Table 4. As the prevalence of
MS and its components varies by age and gender, our
sensitivity/specificity computations were done for each
sex separately, with individuals grouped into two age
groups (<45 yrs, and 45 yrs.) for each gender. In all
age-sex groups, the specificity of detecting the obesity
component of MS (for either definition) by BMI testing
alone is very high (100% for the WHO definition, and ex-
ceeding 96% for the NCEP ATP III definition). However,
the sensitivity is low or at best modest for either defini-
tion. In particular, for the WHO definition of the obe-
sity-component of MS, BMI-testing alone has sensitivity
below 46% in all sex-age categories. For the NCEP ATP
III definition, the men have a somewhat higher sensitiv-
ity (77.1% in men of younger ages, and 60% for the
older). In other words, these statistics indicate that the
chance of false positive rate of detection of the obesity
component of MS (in either definition) by BMI testing
alone is very low, but a substantial proportion of WHO-
and NCEP ATP III-based obesity component will be
missed by BMI testing alone (as sensitivity is never
larger than 77.1%).(Table 4 approximately here)
Discussion and Conclusion
The data presented here show that while BMI (a mea-
sure of generalized obesity) is significantly correlated
with WC and WHR (traditionally regarded as indicators
of centralized adiposity), the poorer correlations of BMI
with WC and WHR indicate that a high value of BMI may
not necessarily capture abdominal obesity (determined
by cut-of values of WHR and/or WC). In particular, the
low (but significant) correlation of BMI with WHR in
both men and women is reflected in the lowest sensitivity
of detecting the obesity component of MS by BMI alone,
when the WHO-definition of MS-obesity is used (Table
4). Before generalizing the high specificity of BMI-based
obesity detection, shown here, we recall that the Mexican
Americans of Starr County, Texas have a very high prev-
alence of diabetes, gallbladder disease, as well as obesi-
ty20,21. Thus, in such a high-risk population, the low false
detection rate of abdominal obesity (i.e., high specificity)
by using an index of generalized obesity (such as BMI) is
not unexpected. The lack of sensitivity of detection of ab-
dominal obesity (the focus of the obesity component of
MS in both WHO and NCEP ATP III definitions), through
the index of general obesity (BMI), however, raises con-
cern, in particular when the disease risk is mainly con-
tributed by abdominal body fat distribution. Substantial
evidence exists suggesting that this is true for metabolic
syndrome, as many studies show that centralized adipos-
ity determines prevalence differences of MS, and its
prognostic value for disease morbidity and mortality18,25.
In summation, data presented here provide an empir-
ical support of the notion that individuals with normal or
moderate BMI do generally have small waist-hip ratio
and waist circumference (resulting in high specificity of
detecting obesity by BMI measurement alone), but indi-
viduals can have high WC and/or WHR without having
high BMI (yielding missing substantial proportions of
centrally obese individuals by BMI testing alone). This is
caused by the fact that centralized obesity is not neces-
sarily captured by a high BMI alone. In contrast, simple
and non-invasive measures of both general and abdomi-
nal obesity (such as BMI, WHR, and WC) exist, and these
may even be adequately assessed by self-reported da-
ta26,27. Thus, large-scale epidemiologic studies should use
both forms of obesity measures to capture the different
dimensions of obesity-related disease risks, such as the
ones signified by metabolic syndrome.
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TABLE 3
PRODUCT MOMENT CORRELATION COEFFICIENTS





BMI – 0.887 0.434
WC 0.889 – 0.704
WHR 0.463 0.557 –
All traits are age-adjusted (n=290 for males; 678 for females);
all correlation coefficients are significant at 1% level. WC =
Waist circumference (in cm), BMI – Body Mass Index = Weight/
Height22
TABLE 4
SENSITIVITY AND SPECIFICITY (BOTH IN PERCENT) OF
DETECTION OF THE OBESITY COMPONENT OF METABOLIC
SYNDROME (MS) ACCORDING TO WHO AND NCEP ATP III
DEFINITIONS BY BMI ALONE
Males Females
<45 yrs. 45 yrs. <45 yrs. 45 yrs.
For detecting MS-obesity as defined by WHO:
Sensitivity 38.0 28.3 34.5 45.9
Specificity 100.0 100.0 100.0 100.0
For detecting MS-obesity as defined by NCEP ATP III:
Sensitivity 77.1 60.0 43.2 49.8
Specificity 96.1 96.7 99.5 100.0
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OSIJETLJIVOST I SPECIFI^NOST INDEKSA TJELESNE MASE KAO DEFINICIJA PRETILOSTI,
KOMPONENTE METABOLI^KOG SINDROMA
S A @ E T A K
Metaboli~ki sindrom (MS) je kombinacija rizi~nih faktora koji su povezani sa nekoliko kroni~nih bolesti. Kompo-
nente MS-a (pretilost, dislipidemija, intolerancija prema karbohidratima, hipertenzija, mikrobumineria) su razli~ite za
razna tuma~enja definicija MS-a. Npr., Svijetska zdravstvena organizacija (WHO) definira pretilost kao glavnu kompo-
nentu MS-a, omjerom struk-bedra ili indeksom tijelesne mase (BMI), dok za razliku od njih Nacionalni centar za edu-
kaciju o kolesterolu (NCEP) definira pretilost opsegom struka. Od kada je indeks tjelesne mase postao uobi~ajna mjera
u epidemiolo{kim studijama, ova studija pokazuje mo`e li se pretilost mjeriti samo indeksom tjelesne mase. Podaci su
pokazali kako je u populaciji sa visokom prevalencijom pretilosti, indeks tjelesne mase bio dovoljan za detekciju u goto-
vo 100% slu~ajeva, ali sa malom osjetljivo{}u (<50%). Pojedinci sa visokim vrijednostima indeksa tijelesne mase, gene-
ralno imaju veliki omjer struk-bedra i {irok opseg struka, dok obrnuto ne mora biti tako. Prema tome, centralizirana
pretilost (rizik za neke kroni~ne bolesti) nije uvijek mjerljiva visokim indeksom tjelesne mase.
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